Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric MATCH erdafitinib subprotocol for FGFR-altered tumors
2021-005604-35Phase 2
- Sponsor
- National Cancer Institute
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erdafitinib in Nonhematologic neoplasms, central nervous system tumor, non-Hodgkin lymphoma (NHL) and 1 more, sponsored by National Cancer Institute. Primary endpoints: Objective response rate and Pharmacokinetics.
02
Drugs
erdafitinib
03
Conditions
Nonhematologic neoplasmscentral nervous system tumornon-Hodgkin lymphoma (NHL)histiocytic disease
Beyond the preview
Go deeper on 2021-005604-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005604-35.